Page 20 - Clinical Development News Today

-  40% of efficacy-evaluable patients (2 out of 5) in the initial cohort of patients with anti-PD-1 refractory melanoma treated with TransCon IL-2...

Dublin, May 31, 2024 (GLOBE NEWSWIRE) -- The

Newly outlined pathway provides a practical, expedient, repeatable immunobridging approach to potential emergency use authorization of serial, novel monoclonal antibodies to prevent and treat...

JJP Biologics has received a positive conclusion on the Clinical Trial Application assessment for a Phase I Study of a potential first-in-class anti-CD89 antagonist, JJP-1212 monoclonal antibody for

JJP Biologics a private biopharmaceutical company developing innovative antibodybased therapies announces a positive decision issued by the European Medicines Agency on the Clinical Trial Application to conduct a phase I clinical study in healthy participants EudraCT 20235086613300 with their potential firstinclass antiCD89 antagonist JJP1212.

- Amir Inamdar, Chief Medical Officer, to appear on panel discussions on June 5 and June 8 - - Ellen James, Director, Clinical Development, to present abstract titled "SPL026 (DMT fumarate) in combination

SAN FRANCISCO and SUZHOU, China, May 28, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announced that picankibart (R & D code: IBI112), a recombinant anti-interleukin 23p19 subunit (IL-23p19) antibody injection, has met all...

VANCOUVER, British Columbia, May 28, 2024 -- Xenon Pharmaceuticals Inc. , a neuroscience-focused biopharmaceutical company, announced data presentations highlighting azetukalner clinical data in...

WAVERLEY PHARMA INC. MANAGEMENT PROXY CIRCULAR and NOTICE OF ANNUAL AND SPECIAL MEETING May 2,...

- Jupiter Bioventures will Gain Exclusive Rights for the Clinical Development, Regulatory Submissions, and Commercialization of Lerociclib for Radioprotection in the US, Europe, Japan, and All Other...